Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 2:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–12 of 12 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: ecopipam HCL Clear all
Completed Phase 2 Interventional Results available

Ecopipam Tablets to Study Tourette Syndrome in Children and Adolescents - Open Label Extension

NCT04114539
View directory record Official record
Conditions
Tourette Syndrome in Children, Tourette Syndrome in Adolescence
Interventions
Ecopipam
Drug
Lead sponsor
Emalex Biosciences Inc.
Industry
Eligibility
6 Years to 18 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
53
States / cities
Dothan, Alabama • Phoenix, Arizona • Anaheim, California + 45 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2024 · Synced Sep 3, 2026, 2:36 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates

NCT04764851
View directory record Official record
Conditions
Drug-Interactions
Interventions
ecopipam HCl ~2mg/kg/day, Cohort 1 Probe Cocktail, Cohort 2 Probe Cocktail, Cohort 3 Probe Cocktail
Drug · Combination Product
Lead sponsor
Emalex Biosciences Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 23, 2021 · Synced Sep 3, 2026, 2:36 AM EDT
Completed Phase 2 Interventional Results available

Ecopipam Tablets to Study Tourette's Syndrome in Children and Adolescents

NCT04007991
View directory record Official record
Conditions
Tourette Syndrome
Interventions
Ecopipam, Placebo
Drug
Lead sponsor
Emalex Biosciences Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
53
States / cities
Dothan, Alabama • Phoenix, Arizona • Anaheim, California + 45 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced Sep 3, 2026, 2:36 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Thorough QT/QTc Study to Evaluate the Effects of Ecopipam (EBS-101) on Cardiac Repolarization

NCT05841160
View directory record Official record
Conditions
QT/QTc
Interventions
Ecopipam Hydrochloride, Moxifloxacin, Placebo
Drug
Lead sponsor
Emalex Biosciences Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Sep 3, 2026, 2:36 AM EDT
Completed Phase 2 Interventional

Effects of Ecopipam or Placebo in Adults With Stuttering (Speak Freely)

NCT04492956
View directory record Official record
Conditions
Childhood-Onset Fluency Disorder (Stuttering)
Interventions
Ecopipam, Placebo
Drug
Lead sponsor
Emalex Biosciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
9
States / cities
Riverside, California • Santa Ana, California • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2022 · Synced Sep 3, 2026, 2:36 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability Comparison of Immediate and Controlled Release Formulations of Ecopipam

NCT01408394
View directory record Official record
Conditions
Healthy
Interventions
Ecopipam immediate release form, 90 mg controlled release form, 180 mg controlled release form
Drug
Lead sponsor
Emalex Biosciences Inc.
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Sep 3, 2026, 2:36 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates for Drug Metabolism and Transport

NCT05334108
View directory record Official record
Conditions
Drug Interaction
Interventions
Ecopipam, Cohort 1 Probe Substrate Cocktail, Cohort 2 Probe Substrate, Cohort 3 Probe Substrate Cocktail
Drug · Combination Product
Lead sponsor
Emalex Biosciences Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 11, 2022 · Synced Sep 3, 2026, 2:36 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette's Disorder

NCT06021522
View directory record Official record
Conditions
Tourette Syndrome
Interventions
Ecopipam
Drug
Lead sponsor
Emalex Biosciences Inc.
Industry
Eligibility
6 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
44
States / cities
Dothan, Alabama • Little Rock, Arkansas • Anaheim, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 3, 2026, 2:36 AM EDT
Available No phase listed Expanded access

Expanded Access Program for Treatment With Ecopipam for Tourette's Disorder

NCT07093541
View directory record Official record
Conditions
Tourettes Disorder, Tourette Disorder
Interventions
ecopipam HCl ~2mg/kg/day
Drug
Lead sponsor
Emalex Biosciences Inc.
Industry
Eligibility
6 Years to 50 Years
U.S. locations
26
States / cities
Glendale, California • San Rafael, California • New Haven, Connecticut + 18 more
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Sep 3, 2026, 2:36 AM EDT
Completed Phase 3 Interventional Results available

Ecopipam Tablets to Study Tourette's Disorder in Children, Adolescents and Adults

NCT05615220
View directory record Official record
Conditions
Tourette Disorder
Interventions
Ecopipam Hydrochloride
Drug
Lead sponsor
Emalex Biosciences Inc.
Industry
Eligibility
6 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
56
States / cities
Dothan, Alabama • Little Rock, Arkansas • Anaheim, California + 41 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 3, 2026, 2:36 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food-effect Study of Ecopipam Pharmacokinetics

NCT06669091
View directory record Official record
Conditions
Food-effect
Interventions
Ecopipam tablet
Drug
Lead sponsor
Emalex Biosciences Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 26, 2025 · Synced Sep 3, 2026, 2:36 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study to Evaluate the Effect of Inhibition of UGTs on the PK of Ecopipam and Its Active Metabolite

NCT04902105
View directory record Official record
Conditions
Drug Interaction
Interventions
ecopipam HCL, Mefenamic acid, Divalproex Sodium ER
Drug
Lead sponsor
Emalex Biosciences Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 21, 2021 · Synced Sep 3, 2026, 2:36 AM EDT